Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets grew its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 110.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 75,400 shares of the biopharmaceutical company's stock after buying an additional 39,599 shares during the period. BNP Paribas Financial Markets' holdings in Ocular Therapeutix were worth $644,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in OCUL. Barclays PLC grew its stake in shares of Ocular Therapeutix by 37.1% in the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company's stock valued at $4,451,000 after buying an additional 138,441 shares during the period. SG Americas Securities LLC boosted its position in shares of Ocular Therapeutix by 58.7% during the 4th quarter. SG Americas Securities LLC now owns 71,698 shares of the biopharmaceutical company's stock worth $612,000 after purchasing an additional 26,511 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Ocular Therapeutix by 11.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company's stock worth $285,000 after purchasing an additional 3,347 shares during the period. Deltec Asset Management LLC boosted its position in shares of Ocular Therapeutix by 0.6% during the 4th quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company's stock worth $22,344,000 after purchasing an additional 16,300 shares during the period. Finally, Rhumbline Advisers boosted its position in shares of Ocular Therapeutix by 2.7% during the 4th quarter. Rhumbline Advisers now owns 213,601 shares of the biopharmaceutical company's stock worth $1,824,000 after purchasing an additional 5,682 shares during the period. Hedge funds and other institutional investors own 59.21% of the company's stock.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,219 shares of Ocular Therapeutix stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $7.18, for a total transaction of $152,352.42. Following the sale, the insider now directly owns 3,499,099 shares in the company, valued at $25,123,530.82. This trade represents a 0.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard L. Md Lindstrom purchased 10,000 shares of the business's stock in a transaction that occurred on Thursday, May 8th. The shares were bought at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the purchase, the director now directly owns 172,704 shares in the company, valued at $1,202,019.84. This represents a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 29,079 shares of company stock worth $208,739 over the last ninety days. Corporate insiders own 2.30% of the company's stock.

Ocular Therapeutix Stock Up 15.3%

Shares of OCUL traded up $1.07 during midday trading on Wednesday, reaching $8.01. The stock had a trading volume of 1,494,312 shares, compared to its average volume of 1,401,145. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -6.06 and a beta of 1.51. The company's fifty day simple moving average is $7.34 and its two-hundred day simple moving average is $7.97. Ocular Therapeutix, Inc. has a 1-year low of $4.79 and a 1-year high of $11.78. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The business had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Equities research analysts expect that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price objective for the company. Needham & Company LLC lowered their price objective on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. William Blair assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They issued an "outperform" rating for the company. Finally, JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Ocular Therapeutix has a consensus rating of "Moderate Buy" and a consensus target price of $16.25.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.